Cline starts collaboration with IFLAI in development of AI software for CellRACE project

Cline Scientific announces that it initiates a project with software company IFLAI to develop custom AI-based software for the cancer diagnostic project, CellRACE.

 Since earlier in 2022, researchers at the University of Gothenburg and Chalmers University of Technology have been collaborating with Cline in exploring whether it is possible to apply algorithms centered around deep learning (a type of machine learning/artificial intelligence) to track and analyze tumor cell behavior and features automatically and objectively. The initial work showed that such a method can be used effectively as a basis for an automated software solution.  Now, Cline takes the next step and outsources the development of an AI software solution to IFLAI, a company with roots in the academic community and documented know-how in this field.

 Cline and IFLAI have agreed on a first-step project to create a tailored solution to the automated analysis of data gathered in the CellRACE project to aid in CellRACE’s further development. This project will be completed in Q4 of 2022. After this, the Cline team will test the software and gather data on a range of tumor cell types. In a following project, this data will be used to enhance the system as it can “learn” a wide range of cancer phenotypes and then ultimately be used as part of an integrated algorithm and measurement system to determine cancer metastatic potential from a patient sample.

We are extremely proud that Cline Scientific have chosen our AI-software for its image analysis work. Cline Scientific is an ideal client for us at IFLAI: a well-established company trying to bring a groundbreaking new technology into the forefront of the industry, limited mainly by the common bottleneck of data analysis. With our AI-based tools, we can push the limits in terms of speed, accuracy, reproducibility and scalability of CellRACE analysis.” – Professor Mattias Goksör, CEO of IFLAI.

About CellRACE
Cline is developing CellRACE, a cell-based cancer diagnostic product that can assess the risk of metastasis. Using the Cline gradient surfaces combined with advanced analytics, CellRACE aims to predict the probability of metastasis in an accurate manner not possible today as well as in a much earlier stage so the patient can start relevant treatment. The product has potential to be used both in breast cancer diagnosis as well as in other forms of metastasizing cancer.

 The analysis method forms part of the overall CellRACE project and its pathway to becoming a marketed product.  Once the analytical method and prediction algorithm has been completed, the next milestone in the CellRACE development journey will consist of conducting a pilot study. Following this, continued product development and final product design will be completed before performing the necessary regulatory approval steps, such as a clinical performance evaluation.

Recent Posts

Contact Us

Hasselvägen 85, Mölnlycke


Get Connected